ストックスクリーナーアプリを入手
7.71
17.89%
1.17
アフターアワーズ：
1.90
-5.81
-75.36%
前日終値:
$6.54
開ける：
$6.47
24時間の取引高:
164.33K
Relative Volume:
1.72
時価総額：
$48.71M
収益：
$28.83M
当期純損益:
$-13.34M
株価収益率:
-5.0724
EPS:
-1.52
ネットキャッシュフロー:
$-7.49M
1週間 パフォーマンス:
+5.91%
1か月 パフォーマンス:
-7.33%
6か月 パフォーマンス:
-23.44%
1年 パフォーマンス:
+399.03%
1日の値動き範囲:
$6.47
$7.7199
1週間の範囲:
$6.17
$7.7199
52週間の値動き範囲:
$1.44
$36.00
Exicure Inc Stock (XCUR) Company Profile
XCUR を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| 0.625 | 0 | 0 | 0 | 0 | 0.00 | |
GOODO
Gladstone Commercial Corporation
|
20.32 | 372.90M | 0 | 0 | 0 | 0.00 |
|
SHMD
Schmid Group N V
|
3.04 | 128.33M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
0.1589 | 360.28M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
DAVEW
Dave Inc
|
1.40 | 0 | 0 | 0 | 0 | 0.00 |
|
DWLD
Davis Select Worldwide ETF
|
41.60 | 0 | 0 | 0 | 0 | 0.00 |
Exicure Inc Stock (XCUR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2021-12-13 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
| 2020-12-18 | 開始されました | BMO Capital Markets | Outperform |
| 2019-11-20 | 開始されました | Guggenheim | Buy |
Exicure Inc (XCUR) 最新ニュース
What makes Exicure Inc. stock price move sharplyStrategic High Profit Opportunities - Newser
Why Exicure Inc. stock attracts strong analyst attentionMarket Beating Strategy - Newser
Exicure Media Files Secondary Offering for Investors - MarketScreener
Exicure files for prospectus offering 5.2 mln common stock offered by selling stockholders - MarketScreener
How Exicure Inc. stock performs during market volatilityFree Wealth-Building Investment Strategies - beatles.ru
Exicure (NASDAQ:XCUR) Stock Price Up 2.3% – Should You Buy? - Defense World
When the Price of (XCUR) Talks, People Listen - news.stocktradersdaily.com
Exicure Plunges 11.36% Despite Russell Microcap Index Inclusion - AInvest
Exicure, Inc.(NasdaqCM: XCUR) added to Russell 3000E Index - MarketScreener
Exicure, Inc. Reports First Quarter 2025 Financial Results - BioSpace
Is Exicure, Inc. overvalued or undervalued? - MarketsMojo
Exicure (NASDAQ:XCUR) Stock Price Down 5.8% – Here’s Why - Defense World
Investors Can Still File Late Claims for Exicure $5.6M Settlement — Here’s How to Get Your Share - TradingView
What's Going On With Exicure Shares Monday? - MSN
Trading (XCUR) With Integrated Risk Controls - news.stocktradersdaily.com
XCURExicure, Inc. Reports Full Year 2024 Financial Results - mx.advfn.com
Exicure faces Nasdaq non-compliance notice By Investing.com - Investing.com South Africa
(XCUR) Trading Report - news.stocktradersdaily.com
Exicure Receives Nasdaq Delinquency Notification - TipRanks
Exicure faces Nasdaq non-compliance notice - Investing.com Australia
Exicure (XCUR) Faces Nasdaq Non-Compliance Due to Delayed Report - GuruFocus
Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q | XCUR Stock News - GuruFocus
Exicure Receives Noncompliance Notice From Nasdaq - marketscreener.com
Exicure (XCUR) Faces Nasdaq Non-Compliance Due to Delayed Report | XCUR Stock News - GuruFocus
Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q - Business Wire
Exicure (NASDAQ:XCUR) Trading Down 4.5% – Here’s Why - Defense World
Exicure (XCUR) Is Paying a $5.6M Settlement to Investors — Here’s How to Get Your Share - TradingView
Exicure Delays 10-Q Filing Amid Acquisition - TipRanks
(XCUR) Investment Analysis and Advice - news.stocktradersdaily.com
Exicure enters strategic convertible bond agreement By Investing.com - Investing.com Nigeria
Exicure Enters Convertible Bond Agreement with Subsidiary - TipRanks
Exicure enters strategic convertible bond agreement - Investing.com
Exicure concludes subject enrolment in trial of GPC-100 for multiple myeloma - Yahoo Finance
Exicure Completes Patient Enrollment in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant | XCUR Stock News - GuruFocus
Exicure Completes Patient Enrollment in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant - Business Wire
Geode Capital Management LLC Purchases Shares of 12,645 Exicure, Inc. (NASDAQ:XCUR) - Defense World
Exicure, Inc. (NASDAQ:XCUR) Sees Significant Drop in Short Interest - Defense World
Investors Can Still File Late Claims for Exicure $5.6M Settlement Payouts - TradingView
Why Exicure Inc. (XCUR) Soared on Monday - MSN
How To Trade (XCUR) - news.stocktradersdaily.com
10 Micro-, Small-Cap Companies Lead Monday’s Charge - Insider Monkey
Exicure, Inc. (NASDAQ:XCUR) Sees Large Drop in Short Interest - Defense World
Exicure Close to Finishing Patient Recruitment in Phase 2 Study of GPC-100 in Multiple Myeloma - MarketScreener
Exicure appoints new independent accounting firm By Investing.com - Investing.com India
Exicure, Inc. (Nasdaq: XCUR) Nears Completion of Phase 2 Study of GPC-100 in Multiple Myeloma - BioSpace
Exicure, Inc. (Nasdaq: XCUR) Nears Completion of Phase 2 Study o - GuruFocus
Exicure appoints new independent accounting firm - Investing.com Australia
Exicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML) - BioSpace
Exicure Inc (XCUR) 財務データ
収益
当期純利益
現金流量
EPS
0.64%
0.37%
大文字化:
|
ボリューム (24 時間):